Single-point plasma or urine dextromethorphan method for determining CYP3A activity

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 9, 2003, Pages 367-373

  Pei Chung Kuo, Benjamin ^a   Yoa Pu Hu, Oliver ^a   Hsiong, Cheng Huei ^a   Pao, Li Heng ^a   Chen, Ting Shien ^a,c   Hung, Chi Feng ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c DEPARTMENT OF HEALTH   (Taiwan)

Author keywords

CYP3A activity; Dextromethorphan metabolic ratio; Plasma ratio; Urine ratio

Indexed keywords

CYTOCHROME P450 3A; DEXTROMETHORPHAN; DRUG METABOLITE; MEDICONE; MORPHINAN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG RELEASE; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; METHODOLOGY; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHENOTYPE; PREDICTION; REPRODUCIBILITY; SIDE EFFECT; SINGLE DRUG DOSE; STUDENT T TEST; URINALYSIS; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADULT; ANTITUSSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DELAYED-ACTION PREPARATIONS; DEXTROMETHORPHAN; HUMANS; MALE; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; SALIVA;

EID: 0346656872     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.373     Document Type: Article

References (11)

1. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999; 48: 716-727.
2. Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P4503A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-556.
3. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
4. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
5. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P4503A probe; II: characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994; 271: 557-566.
6. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450. J Clin Invest 1989; 83: 688-697.
7. Jones DR, Gorski JC, Hamman MA, Hall SD. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromat B: Biomed Appl 1996; 678: 105-111.
8. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 48: 173-182.
9. Hu OYP, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphen method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285: 955-960.
10. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromat B: Biomed Appl 1996; 678: 113-128.
11. Hou ZY, Pickle LW, Meyer PS, Woolsley RL. Salivary analysis for determination of dextromethorphan metabolite phenotype. Clin Pharmacol Ther 1991; 49: 410-419.